GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR

GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested health systems order the test at the point of care, receive results, and manage follow-up within native EHR workflows. The integration is expected to enable approximately 450 health systems to deliver Galleri results within their existing patient portals, aiming to reduce administrative burden and manual processes while improving provider and patient experience.

Galleri is a proactive screening tool performed from a simple blood draw and is described as capable of detecting more than 50 cancer types before symptoms appear. The assay is supported by GRAIL’s targeted methylation-based platform and provides a cancer signal of origin prediction with high accuracy to guide diagnostic work-up when a signal is detected. It is described as the only available MCED test with demonstrated performance in patients screened for cancer. The test requires a prescription and is intended to complement, not replace, recommended screenings; it is recommended for adults with an elevated risk for cancer, such as those aged 50 years and older.

Image: The integration is expected to enable approximately 450 health systems to deliver Galleri results within their existing patient portals (photo courtesy of GRAIL)

Implementation planning began in the first quarter of 2026 with initial integrations and early adopter programs. GRAIL is working with Epic and Amazon Web Services (AWS) to support workflow alignment, training, and deployment, with broad availability expected by the end of 2026.

“Today, recommended screening exists for only five cancers in the U.S., yet more than 70% of deaths are caused by cancers without a recommended screening test. With a scalable integration through Epic, we are reducing operational barriers and making it easier for healthcare providers to incorporate the Galleri test into routine care, with the ultimate goal of supporting early cancer detection before symptoms appear, when outcomes may be better,” said Josh Ofman, MD, MSHS, President at GRAIL.

“Aura helps healthcare organizations collaborate by removing administrative barriers. With GRAIL joining the Epic community, together with healthcare organizations, we can advance early detection and ultimately improve cancer survival rates,” said Alan Hutchison, Vice President at Epic.